Share on LinkedInShare on LinkedIn

ARTICLE · 01 FEBRUARY 2007

Importation Of Claim Limitation Improperly Narrows Scope

Deciding the sole issue of proper construction for the term "dispensing," the U.S. Court of Appeals for the Federal Circuit overturned a decision of no infringement of a medical patent for an automated process.

United StatesIntellectual Property

Deciding the sole issue of proper construction for the term "dispensing," the U.S. Court of Appeals for the Federal Circuit overturned a decision of no infringement of a medical patent for an automated process. A panel majority found that the lower court’s construction requiring "direct dispensing" improperly imported a claim limitation from the specification. Ventana Medical Systems, Inc. v. BioGenex Laboratories, Inc., Case No. 06-1074 (Fed. Cir., Dec. 29, 2006) (Prost, J.; Lourie, J., dissenting).

Ventana’s U.S. Patent No. 6,352,861, directed to an automated dispensing system to perform a variety of biological assays, is one of seven patents that share a common specification. BioGenex manufactures and sells automated staining devices. Ventana filed suit against BioGenex alleging infringement, asserting several claims of the ’861 patent. Based on the claim context and the written description, the district court construed the term "dispensing" as "direct dispensing," meaning that

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from